Virtus Biotech ETF
BBP
20 hedge funds and large institutions have $17.5M invested in Virtus Biotech ETF in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
66% more capital invested
Capital invested by funds: $10.6M → $17.5M (+$6.94M)
25% more funds holding
Funds holding: 16 → 20 (+4)
2.06% more ownership
Funds ownership: 37.68% → 39.73% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.78M |
| 2 |
PCIA
Prime Capital Investment Advisors
Overland Park,
Kansas
|
+$1.8M |
| 3 |
Two Sigma Investments
New York
|
+$835K |
| 4 |
ARC
Advisor Resource Council
Dallas,
Texas
|
+$684K |
| 5 |
CFP
Comprehensive Financial Planning
East Petersburg,
Pennsylvania
|
+$529K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$2.16M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.74M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.05M |
| 4 |
FTUS
Flow Traders U.S.
New York
|
-$463K |
| 5 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
-$363K |
BBP Hedge Fund Activity: Q4 2025 in Review
20 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q4 2025, worth a combined $17.5M — up 66% from $10.6M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BBP positions and 5 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $6.78M. The largest seller was Jane Street, exiting entirely with an estimated $2.16M sold.
- 20 institutional investors held Virtus Biotech ETF (BBP) as of Q4 2025, up from 16 in Q3 2025.
- Funds reported $17.5M of Virtus Biotech ETF stock for Q4 2025, up 66% quarter-over-quarter.
- 9 funds opened new Virtus Biotech ETF positions in Q4 2025 and 5 closed out, a net change of +4 holders.
- The largest Virtus Biotech ETF buyer in Q4 2025 was Royal Bank of Canada, an estimated $6.78M added.
- The largest Virtus Biotech ETF seller in Q4 2025 was Jane Street, an estimated $2.16M sold.
Based on aggregated 13F filings for Q4 2025.